UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $33.
Stocks · News reference
Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And Venetoclax In R/R NPM1m, KMT2Ar, or NUP98r AML In Journal Of Clinical Oncology
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) –– Strong activity across subgroups, including 70%
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $44 to $40.
Syndax Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results. Also, HC Wainwright & Co. lowered its price target on the stock from $40 to $38.
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $40 to $38.